Overview: Episodic Ataxia Hotspot Panel
Introduction: The Episodic Ataxia Hotspot Panel is a diagnostic tool designed to screen for episodic ataxia using whole blood samples. In India, episodic ataxia (types 1 and 2) is rare but underrecognized in families with paroxysmal ataxia, vertigo, or myokymia, caused by mutations in KCNA1 (EA1) and CACNA1A (EA2). High morbidity from underdiagnosis in rural/low-SES neurological patients, limited genetic labs, delayed acetazolamide or 4-aminopyridine therapy leading to falls or progression. Per molecular pathology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for hotspot mutations over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected channelopathies. This diagnostic falls under neurological genetic screening and targets patients with recurrent ataxia episodes or family history, addressing accurate detection to guide symptomatic therapy and counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing hereditary neurological burden. Its whole blood-based approach ensures reliable mutation analysis.
Other Names: Ataxia Hotspot Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: Channelopathy gene testing; in India, reported in ataxia clinics.
Purpose: The test assesses 2 parameters including CACNA1A mutation to guide episodic ataxia diagnosis, detect hotspots, inform management.
Test Parameters: 1. CACNA1A Mutation, 2. KCNA1 Mutation.
Pretest Condition: No fasting required; patients should report episodic ataxia, vertigo, or family history.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on episode triggers, duration, family neurological history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed ataxia including progression, benefits of confirmation, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive mutation confirms episodic ataxia, necessitating specialist input. Negative may require follow-up if symptoms suggestive.
Specialist Consultation: Neurologists or geneticists should be consulted for management.
Additional Supporting Tests: EEG, MRI for confirmation.
Test Limitations: Limited to hotspots; comprehensive approach required.
References: Indian Journal of Neurology 2024, Ataxia Studies India 2023.
